BenzingaDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 10-21 21:36:12·⟳ 抓取 10-21 21:36:37 +25s·⚡ 决策 10-22 06:06:21 +8h29m·5.6 天前
Benzinga汇总Intuitive Surgical Q3财报后分析师目标价调整，核心财报催化此前已处理且无新增事实
本信号为Benzinga对Q3财报后卖方目标价的二手汇总，4家分析师均维持原评级、仅微调目标价（两升两降），未提供超出10-20已处理8-K/财报的任何新增事实；财报beat-but-guide-mixed的反应已在盘后及次日盘中完成重定价，当前盘后不可成交，做多做空均无正期望。
📄 原文Benzinga↗ 原文
These Analysts Revise Their Forecasts On Intuitive Surgical After Q3 Results
Intuitive Surgical Inc (NASDAQ:ISRG) on Tuesday posted better-than-expected financial results for the third quarter. In…
不做 Intuitive Surgical（ISRG.US）
本条仅为Q3财报后分析师目标价二手汇总（评级全部维持、目标价两升两降），无任何相对10-20已处理财报的新增事实；beat-but-guide-mixed已在盘后和次日盘中（-5.8%）完成重定价，且当前盘后不可成交，做多对抗利润率/指引下行、做空对抗强劲beat与利空出尽，两侧均无正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是已处理财报的分析师点评汇总而非新催化：营收/EPS双超预期但指引收窄、含4.5亿美元和解费，市场已在盘后和次日（-5.8%）完成定价。目标价两升两降且评级均不变，无增量edge，不做。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 high · price-in 风险 high ↗
主要风险
- 若后续电话会披露新的订单/放置量或利润率趋势信息，可能形成独立于本汇总的新催化，需另行研判
- 分析师目标价整体仍高于现价（400-550美元），短期若市场聚焦beat存在超跌反弹风险，不宜追空
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-10-20 · 影响 weakens
已处理记录显示：4.5亿美元一次性和解费、调整后营业利润率同比降12.5pp、隐含Q4毛利率降至约68%（关税拖累约0.9pp），构成对抄底的实质反证。
检索:Intuitive Surgical Q3 2026 反垄断和解 毛利率指引 营业利润率 下调 - 做空前查反向 · 来源 filing · 日期 2026-10-20 · 影响 weakens
营收同比+22%双超预期、放置546台（含315台da Vinci 5）、Ion手术量+31%、和解费为已披露一次性事项，追空面临利空出尽与超跌反弹风险。
检索:Intuitive Surgical Q3 revenue beat procedure growth placement da Vinci 5
先例如何影响了这次决策
对本次决策的影响:确认无新edge，支持AVOID，未据此设定任何止盈止损。
方向:本条无新增催化，不需要外部先例重新定价；财报本体的反应已在价格中。
涨幅量级:无可归因于本汇总的增量幅度
形态:卖方在财报后两升两降目标价、评级不变的汇总通常不构成独立交易事件。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,846 ms
{"result": "search_processed_events:agent query=`intuitive surgical isrg q3 2026 earnings results revenue beat | isrg da vinci procedure guidance 14% 15% analyst price target revisions`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、27444 条本臂决策(完整)，返回 2 条候选。\n• 10-20 21:09 UTC(北京 10-21 05:09) [bm25:43%] 不做 ISR
原文全文
展开原文 · 1,790 字
Intuitive Surgical Inc (NASDAQ:ISRG) on Tuesday posted better-than-expected financial results for the third quarter.
Intuitive Surgical reported revenue of $3.05 billion for the quarter, beating analyst estimates of $2.91 billion, according to Benzinga Pro. The robotic-assisted surgery company reported third-quarter adjusted earnings of $3.00 per share, beating estimates of $2.64 per share.
"Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period," said Dave Rosa, CEO of Intuitive Surgical.
Intuitive Surgical expects full-year 2026 worldwide da Vinci procedures to increase approximately 14% to 15%, and gross profit margin to be between 68.7% and 69.3% of revenue. The company previously guided for 2026 da Vinci procedures growth of 13.5% to 15.5%.
Intuitive Surgical shares fell 5.8% to trade at $413.12 on Wednesday.
These analysts made changes to their price targets on Intuitive Surgical following earnings announcement.
- Baird analyst David Rescott maintained the stock with an Outperform rating and raised the price target from $513 to $550.
- Mizuho analyst Anthony Petrone maintained the stock with a Neutral and lowered the price target from $415 to $400.
- RBC Capital analyst Kendall Au maintained the stock with an Outperform rating and cut the price target from $575 to $550.
- Barclays analyst Christopher Pasquale maintained the stock with an Overweight rating and raised the price target from $485 to $500.
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Intuitive Surgical reported revenue of $3.05 billion for the quarter, beating analyst estimates of $2.91 billion, according to Benzinga Pro. The robotic-assisted surgery company reported third-quarter adjusted earnings of $3.00 per share, beating estimates of $2.64 per share.
"Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period," said Dave Rosa, CEO of Intuitive Surgical.
Intuitive Surgical expects full-year 2026 worldwide da Vinci procedures to increase approximately 14% to 15%, and gross profit margin to be between 68.7% and 69.3% of revenue. The company previously guided for 2026 da Vinci procedures growth of 13.5% to 15.5%.
Intuitive Surgical shares fell 5.8% to trade at $413.12 on Wednesday.
These analysts made changes to their price targets on Intuitive Surgical following earnings announcement.
- Baird analyst David Rescott maintained the stock with an Outperform rating and raised the price target from $513 to $550.
- Mizuho analyst Anthony Petrone maintained the stock with a Neutral and lowered the price target from $415 to $400.
- RBC Capital analyst Kendall Au maintained the stock with an Outperform rating and cut the price target from $575 to $550.
- Barclays analyst Christopher Pasquale maintained the stock with an Overweight rating and raised the price target from $485 to $500.
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
87384a8eb9· 2026-10-22 06:06 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前